Peg-Interferon A-2A (RO 25-8310)


Combined with:

Ribavirin

Indications and Reactions:

Role Indications Reactions
Primary
Hepatitis C 67.3%
Drug Use For Unknown Indication 13.3%
Depression 4.1%
Hypertension 2.9%
Anxiety 2.2%
Insomnia 1.4%
Prophylaxis 1.1%
Hepatitis C Virus 1.0%
Pain 0.9%
Sleep Disorder Therapy 0.7%
Thyroid Disorder 0.7%
Hiv Infection 0.6%
Nausea 0.6%
Diabetes Mellitus 0.6%
Back Pain 0.5%
Blood Pressure Increased 0.5%
Somnolence 0.5%
Anaemia 0.4%
Asthma 0.4%
Blood Pressure 0.4%
White Blood Cell Count Decreased 34.9%
Weight Decreased 12.0%
Vomiting 6.8%
Death 5.7%
Thrombosis 4.0%
Pain 3.2%
Pyrexia 3.2%
Suicidal Ideation 3.0%
Convulsion 2.8%
Vision Blurred 2.8%
White Blood Cell Count Increased 2.7%
Red Blood Cell Count Decreased 2.5%
Loss Of Consciousness 2.3%
Pneumonia 2.3%
Renal Failure 2.3%
Pancytopenia 2.1%
Syncope 2.1%
Haemoptysis 1.9%
Hepatic Neoplasm Malignant 1.7%
Platelet Count Decreased 1.7%
Secondary
Hepatitis C 67.7%
Drug Use For Unknown Indication 7.6%
Hepatitis C Virus 3.8%
Hypertension 3.8%
Thyroid Disorder 3.2%
Depression 2.5%
Diabetes Mellitus 2.5%
Anxiety 1.3%
Anaemia 0.8%
Insomnia 0.8%
Sleep Disorder Therapy 0.8%
Asthma 0.6%
Back Pain 0.6%
Glomerulonephritis 0.6%
Pain 0.6%
Prophylaxis 0.6%
Antidepressant Therapy 0.4%
Bipolar Disorder 0.4%
Blood Pressure 0.4%
Gastric Disorder 0.4%
White Blood Cell Count Decreased 42.9%
Thrombotic Thrombocytopenic Purpura 6.9%
Suicidal Ideation 6.0%
Pleural Effusion 4.3%
Hepatic Neoplasm Malignant 3.9%
Vomiting 3.9%
Weight Decreased 3.9%
Upper Respiratory Tract Inflammation 3.4%
Pneumonia 3.0%
Whiplash Injury 2.6%
Loose Tooth 2.1%
Multiple Sclerosis 2.1%
Neoplasm 2.1%
Pyrexia 2.1%
Rash Pruritic 2.1%
Cholelithiasis 1.7%
Lymphoma 1.7%
Malignant Melanoma 1.7%
Rectal Cancer 1.7%
Subarachnoid Haemorrhage 1.7%

Drug Data